Compare Abeona Therapeutics Inc (ABEO) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Advanced Drainage Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.68B). The key difference: Advanced Drainage Systems Inc is far larger — about 25.2× Abeona Therapeutics Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WMS | |
|---|---|---|
Market Cap | $424.33M | $10.68B |
Sector | Health | Industrials |
52-Week High | $7.45 | $175.38 |
52-Week Low | $4.17 | $129.50 |
Enterprise Value | $279.23M | $12.29B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Advanced Drainage Systems (WMS) trades at $143.95, down 3.03% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news highlights Q1 fiscal 2027 sales growth of 21% and consistent dividend payments, though cash flow turned negative in 2025 due to increased investing activity.
The outlook is mixed; analyst consensus is a Buy with a $185.86 price target, but near-term risks include volatile cash flows and high valuation multiples. Upside potential hinges on execution of growth initiatives and infrastructure demand, while margin pressure and economic sensitivity pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
